6533b85ffe1ef96bd12c1a52

RESEARCH PRODUCT

P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer

Markus MoehlerDaniel Virgil Thomas CatenacciLiang ShenM. Koshiji RosalesY. KangH.c. ChungHarry H. Yoon

subject

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMargetuximabAnti pd 1CancerHematologyGastroesophageal Junctionmedicine.diseaseFirst line therapyOncologyInternal medicinemedicinebusinesshttps://doi.org/10.1016/j.annonc.2020.04.424